Losartan use during pregnancy

Both the FDA and TGA recommend avoiding the use of Losartan during pregnancy due to the potential risks to the fetus, particularly during the second and third trimesters.

 Pregnancy    Category D         ( by FDA )

                       Category  D        (AU TGA )

              

Losartan is classified as FDA pregnancy category D. This classification indicates that there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.